Key result
Ioversol 300 reduced the total iodine burden and lowered costs by 9.1% (185.85 vs 204.40 Swiss francs, P<0.001) with unaltered image quality compared to ioversol 350.
Why the study?
Does ioversol 300 reduce iodine burden and costs without compromising image quality compared to ioversol 350 in patients undergoing cardiac angiography?
RCT (n=300)
double-blind
randomized
Yes
Does ioversol 300 reduce iodine burden and costs without compromising image quality compared to ioversol 350 in patients undergoing cardiac angiography?
Absolute Event Rate: 185.85% vs 204.4%
p-value: p=<0.001
Ioversol 300 provides equivalent image quality to ioversol 350 for cardiac angiography while significantly reducing iodine burden and procedural costs.
Supports ioversol 300 for cardiac angiography to reduce iodine burden and costs; RCT confirms equivalent image quality versus 350.
Objective: To compare the diagnostic yield and the costs of a contrast agent with a lower iodine concentration, ioversol 300, versus the routinely used ioversol 350. Design and patients: In a prospective, randomized, double‐blind study, ioversol 300 (group A patients) containing 300 mg/mL of iodine was compared with the commonly used ioversol 350 (group B patients) containing 350 mg/mL of iodine using a visual scoring system (1 = worst, 5 = best) with respect to image quality, fluoroscopy time, and amount of contrast and iodine used for coronary angiography and left ventriculography in 300 consecutive patients. The study was performed in two catheterization laboratories of different technical standards (high resolution with digital image treatment stored on Super VHS tapes in patients 1–170 and conventional 35‐mm cine films in patients 171–300). Results: In group A, the quality scores for coronary angiography and left ventriculography were 4.4 (±0.7) and 4.0 (±0.8) in patients 1–170 and 3.7 (±0.8) and 4.0 (±0.8) in patients 171–300, whereas in group B the values were 4.4 (±0.6) and 4.5 (±0.6) for patients 1–170 and 3.7 (±0.8) and 4.0 (±0.8) for patients 171–300 (all NS). Fluoroscopy time (min) in group A was 9.4 (±6.1) in patients 1–170 and 11.1 (±8.8) in patients 171–300 and 11.0 (±6.6) and 10.1 (±5.7) in group B, respectively (NS). Contrast volume (mL) and iodine amount (g) in group A were 201.1 (±55.4) and 60.3 (±16.6) for patients 1–170 and 198.2 (±46.4) and 59.3 (±13.9) for patients 171–300 (NS). In group B, the corresponding numbers were 202.4 (±61.7) and 70.8 (±21.6) in patients 1–170 and 200.0 (±49.4) and 70.0 (±17.3) in patients 171–300 (P = 0.0042, patients 1–170 and P = 0.0002, patients 171–300 for iodine amount). The average cost of the contrast agent (Swiss francs) was 185.85 ± 47.9 in group A and 204.40 ± 52.4 in group B (P < 0.001). Conclusion: The use of ioversol 300 reduced the total iodine burden for cardiac catheterization with unaltered image quality and fluoroscopy time, while the costs were reduced by 9.1%.
No takes yet. Share an insight, caveat, or question.
Waser et al. (1998) conducted an RCT in Cardiac Angiography (n=300). Ioversol 300 vs. Ioversol 350 was evaluated on Average cost of the contrast agent (Swiss francs) (p=<0.001). Ioversol 300 reduced the total iodine burden and lowered costs by 9.1% (185.85 vs 204.40 Swiss francs, P<0.001) with unaltered image quality compared to ioversol 350.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: